CorMedix (CRMD) Therapeutics announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common stock. The repurchase program is authorized through December 31, 2027. CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
- CorMedix price target lowered to $13 from $18 at H.C. Wainwright
- CorMedix price target lowered to $13 from $22 at RBC Capital
- P/E Steals: 3 Overlooked Stocks Ready to Surge Over 100% in 2026
- Cormedix: Near-Term Reimbursement Headwinds but Compelling Long-Term Upside Supports Buy Rating and $18 Target